that's the last major break through apart from mimentine. it was like 25 years ago nhibitors and 13 years ago for mimentine. those drugs are available for people with down syndrome. but i think there are underutilized. it's also fair to say that the effects -- the side effects of those drugs may be different with people that has down syndrome than the general population. the bottom line that you need to hear, in spite of many, mall billions of dollars invested, we're not yet there with disease modifying treatments for alzheimer's disease. and my argument is that here's a chance for people with down syndrome to change that. mr. cole: you're generous to recognize that. thank you. [laughter] i next want to go to my good friend from the great state of alabama, mrs. roby, for any questions she cares to ask. mrs. roby: thank you, chairman cole, for convening this informative hearing today and to all of you on the panel for sharing your information and, mr. stephens, for your personal testimony. i appreciate it so much. but to highlight the importa